Professionals 266 results
- Yulia Makarova
- Partner of Winston & Strawn London LLP
- +44 20 7011 8803
- vCard
Partner of Winston & Strawn London LLP
Capabilities 77 results
Practice Area
Financial Innovation & Regulation
Practice Area
Privacy: Regulated Personal Information (RPI)
Practice Area
Experience 10 results
Experience
|March 18, 2025
Experience
|February 10, 2025
US$600 million Total Play Telecomunicaciones S.A.P.I. de C.V. Offer to Exchange Senior Notes
Experience
|May 10, 2024
Insights & News 2,215 results
Product Liability & Mass Torts Digest
|August 22, 2025
|5 Min Read
In what appears to be the first case to consider the issue, an Eastern District of Missouri court recently rejected the argument that the Supreme Court’s Loper Bright Enterprises v. Raimondo decision overruling Chevron deference undermines the basis for express preemption in medical device cases.
Webinar
|August 21, 2025, 12:00 PM E.T.
Tax Impacts
|August 20, 2025
|7 Min Read
Crypto Tax Update: New Tax Rules on the Horizon?
On July 30, President Trump’s Working Group on Digital Assets released its comprehensive “Strengthening American Leadership in Digital Financial Technology” report (the Report). The 160-plus-page report sets forth a series of recommendations seeking to “ensure crypto becomes a hallmark of the new American Golden Age” while outlining a proposed framework for regulating digital assets. A key section of the Report focuses on the taxation of digital assets and sets forth proposals on the modernization of the tax framework to better align with the realities of the digital asset ecosystem. The proposals address a range of substantive tax issues, including the classification of digital assets for tax purposes, the timing and character of income from mining and staking activities, and the tax treatment of stablecoins, and also recommends updates to taxpayer and third-party reporting requirements.
Other Results 109 results
Law Glossary
Law Glossary
What Is the Standard for the FDA to Grant a Biosimilar License?
Law Glossary
What Is the Standard for the FDA to Grant a Generic Drug License?